CXCL3. a member of the CXC chemokine family (also known as GROγ or MIP-2β), is a small cytokine involved in immune regulation, inflammation, and cancer progression. It binds primarily to the CXCR2 receptor, mediating neutrophil recruitment, angiogenesis, and tissue repair. Dysregulation of CXCL3 is linked to chronic inflammatory diseases (e.g., arthritis, colitis), tumor growth, metastasis, and immune microenvironment modulation.
CXCL3 antibodies are essential tools for detecting and quantifying CXCL3 expression in research. They are widely used in techniques like Western blot (WB), ELISA, and immunohistochemistry (IHC) to study its role in disease models. Polyclonal and monoclonal antibodies are available, typically generated in hosts like rabbits or mice. Specific clones are validated for specificity using knockout controls or blocking peptides.
These antibodies aid in exploring CXCL3's functional interactions, such as its crosstalk with tumor-associated macrophages or endothelial cells in cancer. Researchers also utilize them to assess CXCL3's potential as a biomarker for disease severity or therapeutic response. Recent studies focus on neutralizing antibodies to block CXCR2/CXCL3 signaling in inflammatory disorders or to enhance anti-tumor immunity. Proper validation, including species reactivity and cross-reactivity checks, is critical for experimental accuracy.